The scope of the ADME Toxicology Testing Market encompasses systemic toxicity, hepatotoxicity, renal toxicity, neurotoxicity, and genotoxicity assessments across small molecules, cell therapies, and biologics. Hepatotoxicity remains a primary focus due to drug-induced liver injury (DILI) being a leading cause of drug withdrawal. Concurrently, the growing development of biotherapeutics and complex drug delivery vehicles has led to increased demand for targeted organ toxicity screens and specialized membrane permeability assays.

Critical Toxicity Assessment Areas

1. Hepatotoxicity Screening: Utilizing human hepatocytes and liver-on-chip platforms to predict metabolic clearance and toxic liver metabolites.

2. Systemic & Organ Toxicity: Evaluating systemic bioavailability, blood-brain barrier permeability, and cardiovascular safety parameters.

3. Drug-Drug Interaction (DDI): Mapping CYP450 induction/inhibition and major efflux/uptake transporter pathways to prevent dangerous drug combinations.